Trader’s Watch List: NephroGenex, Inc. (NASDAQ:NRX), SciQuest, Inc. (NASDAQ:SQI), The Kraft Heinz Company (NASDAQ:KHC), PTC Therapeutics, Inc. (NASDAQ:PTCT), MannKind Corp.

NephroGenex, Inc. (NASDAQ:NRX), announced that its Board of Directors has made a determination to pause the clinical program of the Company’s product candidate oral Pyridorin® for the treatment of diabetic nephropathy, effect a restructuring of its operations, and implement a strategic transaction. The Board of Directors made this determination in light of the remaining trial costs, the Company’s cash balance and the condition of the capital markets.

NephroGenex, Inc. (NASDAQ:NRX) belongs to Healthcare sector. Its weekly performance is -43.11%. On last trading day company shares ended up at $0.62.

SciQuest, Inc. (NASDAQ:SQI), announced its Board of Directors has approved a share repurchase program that enables the company to repurchase up to $30 million of its outstanding common stock. The amount and timing of specific repurchases are subject to market conditions, applicable legal requirements and other factors. The share program is scheduled to expire on December 31, 2017, although purchases may be suspended or discontinued at any time prior to the expiration date.

SciQuest, Inc. (NASDAQ:SQI) shares moved up 5.26% in last trading session and ended the day at $12.41. SQI Gross Margin is 68.10% and its return on assets is 0.70%. SciQuest, Inc. (NASDAQ:SQI) quarterly performance is -2.05%.

Kraft Heinz (NASDAQ: KHC) reported Q4 EPS of $0.62, versus $0.56 reported last year. Revenue for the quarter came in at $7.12 billion, versus $7.5 billion reported last year.

On 26 February, The Kraft Heinz Company (NASDAQ:KHC) shares moved up 3.84% and was closed at $77.84. The Kraft Heinz Company (NASDAQ:KHC) year to date (YTD) performance is 6.98%.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the company has had multiple discussions with the German Federal Association of the Statutory Health Insurances (GKV-SV) over the last several months to come to agreement on pricing and reimbursement. Recently, these discussions transitioned into an arbitration process, which did not lead to an acceptable agreement. As a result, PTC is considering delisting Translarna from the German pharmacy ordering system. Under these circumstances, patients and healthcare professionals may be able to access Translarna through a reimbursed importation pathway possible under German law, thus minimizing any access issues for German patients while maintaining a sustainable price.

PTC Therapeutics, Inc. (NASDAQ:PTCT) ended the last trading day at $7.99. Company weekly volatility is calculated as 28.94% and price to cash ratio as 7.39. PTC Therapeutics, Inc. (NASDAQ:PTCT) showed a weekly performance of -72.30%.

MannKind (NASDAQ: MNKD) founder Alfred Mann was said to have passed away, according to the LA Times. Mann, 90, recently resigned as Executive Chairman of MannKind. According to the article, Mann founded 17 companies over his 70 years in business. Fields ranged from aerospace to pharmaceuticals to medical devices.

MannKind Corp. (NASDAQ:MNKD) shares fell -4.63% in last trading session and ended the day at $1.03. MNKD return on assets is -36.90%. MannKind Corp. (NASDAQ:MNKD) quarterly performance is -53.18%.

Leave a Reply

Your email address will not be published. Required fields are marked *